摘要
目的探讨二代基因测序技术检测急性髓系白血病患者细胞因子受体样因子2(CRLF2)、FMS样酪氨酸激酶3(FLT3)及C-KIT突变的价值。方法选择2017年1月至2020年1月在我院接受治疗的78例急性髓系白血病患者为研究对象,采用二代基因测序技术检测CRLF2、FLT3及C-KIT突变情况。比较CRLF2、FLT3及C-KIT不同突变类型患者的临床参数;比较CRLF2、FLT3及C-KIT不同突变类型患者治疗≤2个疗程的完全缓解率和复发率。结果78例患者中CRLF2突变11例,突变率为14.10%,正常核型突变率高于异常核型,差异具有统计学意义(P<0.05);FLT3突变9例,突变率为11.54%,正常核型突变率高于异常核型,差异具有统计学意义(P<0.05);C-KIT突变6例,突变率为7.69%,正常核型突变率低于异常核型,差异具有统计学意义(P<0.05)。CRLF2不同突变类型患者的年龄、白细胞计数、血小板计数比较,差异具有统计学意义(P<0.05);FLT3不同突变类型患者的白细胞计数比较,差异具有统计学意义(P<0.05);C-KIT不同突变类型患者的血红蛋白水平比较,差异具有统计学意义(P<0.05)。开展随访跟踪共计76例患者可评价干预效果,CRLF2不同突变类型患者治疗≤2个疗程的完全缓解率和复发率比较,差异无统计学意义(P>0.05);FLT3突变阳性患者治疗≤2个疗程的完全缓解率低于突变阴性患者,复发率高于突变阴性患者,差异具有统计学意义(P<0.05);C-KIT不同突变类型患者治疗≤2个疗程的完全缓解率比较,差异无统计学意义(P>0.05);C-KIT突变阳性患者复发率高于突变阴性患者,差异具有统计学意义(P<0.05)。结论急性髓系白血病患者CRLF2、FLT3及C-KIT突变较为常见,利用二代基因测序技术开展上述基因突变检测有助于指导临床治疗及预后评估。
Objective To explore the value of second-generation gene sequencing technology in detecting cytokine receptor like factor 2(CRLF2),FMS-like tyrosine kinase 3(FLT3)and C-KIT mutation in patients with acute myeloid leukemia.Methods A total of 78 patients with acute myeloid leukemia treated in our hospital from January 2017 to January 2020 were selected as the research objects.The CRLF2,FLT3 and C-KIT mutation were detected by second-generation gene sequencing technology.The clinical parameters of patients with different mutation types of CRLF2,FLT3 and C-KIT were compared;the complete remission rate after treatment for≤2 courses and recurrence rate of patients with different mutation types of CRLF2,FLT3 and C-KIT were compared.Results There were 11 cases of CRLF2 mutation in 78 patients,with a mutation rate of 14.10%,the mutation rate of normal karyotype was higher than that of abnormal karyotype,and the difference was statistically significant(P<0.05);there were 9 cases of FLT3 mutation,with a mutation rate of 11.54%,the mutation rate of normal karyotype was higher than that of abnormal karyotype,and the difference was statistically significant(P<0.05);there were 6 cases of C-KIT mutation,with a mutation rate of 7.69%,the mutation rate of normal karyotype was lower than that of abnormal karyotype,and the difference was statistically significant(P<0.05).There were significant differences in age,white blood cell count and platelet count among patients with different mutation types of CRLF2(P<0.05);there was significant difference in white blood cell count among patients with different mutation types of FLT3(P<0.05);there was significant difference in hemoglobin level among patients with different mutation types of C-KIT(P<0.05).A total of 76 patients were followed up to evaluate the intervention effect.There were no statistically significant differences in the complete remission rate after treatment for≤2 courses and recurrence rate of patients with different mutation types of CRLF2(P>0.05);the complete remission rate after treatment for≤2 courses of FLT3 mutation positive patients was lower than that of mutation negative patients,the recurrence rate was higher than that of mutation negative patients,and the differences were statistically significant(P<0.05);there was no statistically significant difference in the complete remission rate after treatment for≤2 courses of patients with different mutation types of C-KIT(P>0.05);the recurrence rate of C-KIT mutation positive patients was higher than that of mutation negative patients,and the difference was statistically significant(P<0.05).Conclusion CRLF2,FLT3 and C-KIT mutation are common in patients with acute myeloid leukemia.Detection of these mutation using second-generation gene sequencing technology is helpful to guide clinical treatment and prognosis evaluation.
作者
常渊媛
杨亚锋
CHANG Yuanyuan;YANG Yafeng(Hematology Department,Yulin No.2 Hospital,Yulin 719000,China)
出处
《临床医学研究与实践》
2023年第7期97-100,共4页
Clinical Research and Practice
